Omeros Target of Unusually Large Options Trading (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) was the target of some unusual options trading on Thursday. Stock investors acquired 12,612 call options on the stock. This represents an increase of 235% compared to the average volume of 3,762 call options.

Omeros Stock Performance

NASDAQ:OMER traded down $0.16 during trading on Friday, reaching $17.19. The company’s stock had a trading volume of 3,673,375 shares, compared to its average volume of 2,166,098. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. The firm has a 50 day moving average of $10.89 and a 200-day moving average of $11.54. Omeros has a 12 month low of $3.94 and a 12 month high of $18.14.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million. Equities research analysts forecast that Omeros will post -0.94 earnings per share for the current fiscal year.

More Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
• Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
• Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
• Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.

Analyst Upgrades and Downgrades

OMER has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Finally, Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Insiders Place Their Bets

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the transaction, the director directly owned 35,067 shares of the company’s stock, valued at $407,127.87. The trade was a 17.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. State of Wyoming purchased a new stake in shares of Omeros during the 4th quarter worth approximately $25,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Omeros in the 2nd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Omeros in the fourth quarter valued at approximately $33,000. Assetmark Inc. purchased a new position in Omeros in the first quarter valued at approximately $38,000. Finally, Tower Research Capital LLC TRC grew its holdings in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.